Amended Current Report Filing (8-k/a)
August 26 2019 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 2)
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 23, 2019
Date of Report (Date of earliest event reported)
GALA PHARMACEUTICAL INC.
(Exact name of registrant as specified in
its charter)
|
NEVADA
|
000-52044
|
42-1771014
|
|
(State or other jurisdiction of
|
(Commission File
|
(IRS Employer Identification No.)
|
|
incorporation)
|
Number)
|
|
|
|
|
|
|
|
|
|
|
18881 Von Karman Avenue, Suite 1440, Irvine, California
|
92612
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(775) 321-8238
Registrant's telephone number, including
area code
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form
8-K fi ling is intended to simultaneously satisfy the fi ling obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
N/A
|
N/A
|
N/A
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
[ ]
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
This form 8-K/A is being filed as
an amendment (“Amendment No. 2”) to the current Report on Form 8-K filed by Gala Pharmaceutical, Inc. on July
9, 2018 (the “Original Filing”) and the Amendment No. 1 filed on July 20, 2018. The purpose of this Amendment No.
3 to clear of any reporting errors made in past filings concerning Maqsood Rehman’s employment agreements with
the company.
ITEM 8.01 OTHER EVENTS
The following is the employment history between
Gala Pharmaceutical, Inc. and Maqsood Rehman:
History of Agreements between GLPH and Maqsood
Rehman:
|
|
•
|
June
13, 2017: Mr. Rehman hired as chief Operation Officer (COO) of GLPH. He is awarded 1,500,000 common shares
of GLPH annually and $15,000 monthly (original agreement).
|
|
|
•
|
November
27, 2017: Mr. Rehman was offered the position of Chief Executive Officer (CEO) of GLPH (Amendment No. 1 of the original agreement).
|
|
|
•
|
January
5, 2018: Mr. Rehman was awarded 5,000,000 common shares of GLPH for accepting the CEO position. (Amendment No. 2 of the original
agreement).
|
|
|
•
|
The
terms of the CEO position remain the same as in the original agreement.
|
|
|
•
|
The
purpose of this Agreement (Amendment No. 3) is to include all the past amendments with the proper dates.
|
ITEM 9.01 FINANCIAL
STATEMENTS AND EXHIBITS
The following exhibit is attached as part
of this report:
Exhibit No. Description
10.1 Amendment No. 3 to Agreement for Corporate Executive
Signatures
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
GALA PHARMACEUTICAL INC.
|
|
|
|
|
|
Date: August 23, 2019
|
By:
|
/s/ Maqsood Rehman
|
|
|
|
Maqsood Rehman
|
|
|
Title:
|
Chief Executive Officer
|